On-target PD effects were consistent with PD-L1 inhibition and data reported by anti-PD-(L)1 mAbs. Preliminary anti-tumor activity was observed, and further studies are warranted to explore the efficacy in a larger number of patients.

over 1 year ago

Clinical • P1 data • Metastases

MSI (Microsatellite instability) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL2 (Interleukin 2)

MSI-H/dMMR

ABSK043

2years

Broad anti-tumor activity of a potent and selective small molecule antagonist of PD-L1 ABSK043 in combination with other agents in preclinical models (SITC 2022)

Results ABSK043 demonstrated strong in vivo synergy with several therapeutic agents such as carboplatin, a key component of the widely used CRC standard-of care chemotherapy treatment regimen, as well as other target therapy or immune-oncology agents. Conclusions Taken together, these data for the first time demonstrated broad combination synergy of a small molecule PD-L1 antagonist with other agents and provided basis for potential clinical evaluation of these combination treatment for cancer patients.

2 years ago

Preclinical • Combination therapy

PD-L1 (Programmed death ligand 1)

carboplatin • ABSK043

over2years

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (clinicaltrials.gov)

P1, N=60, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting

over 2 years ago

Enrollment open

MSI (Microsatellite instability)

MSI-H/dMMR

ABSK043

over3years

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (clinicaltrials.gov)

P1, N=60, Not yet recruiting, Abbisko Therapeutics Co, Ltd

over 3 years ago

Clinical • New P1 trial

MSI (Microsatellite instability)

MSI-H/dMMR

ABSK043